Kezar Life Sciences, Inc. (KZR)
7.33
-0.04
(-0.54%)
USD |
NASDAQ |
Apr 17, 16:00
7.34
+0.01
(+0.14%)
After-Hours: 20:00
Kezar Life Sciences SG&A Expense (Quarterly) : 3.248M for Dec. 31, 2025
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Apellis Pharmaceuticals, Inc. | 147.10M |
| ACADIA Pharmaceuticals, Inc. | 155.62M |
| Alnylam Pharmaceuticals, Inc. | 325.37M |
| Savara, Inc. | 12.53M |
| BioMarin Pharmaceutical, Inc. | 446.21M |